Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FET PET for Localization of Pituitary Adenomas in Cushing Disease
NCT07460232Phase 1Recruiting
- Sponsor
- Mayo Clinic
- Start
- Apr 2026
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of O-(2-[18F]fluoroethyl)-L-tyrosine in Cushing's disease (CD) and pituitary adenoma, sponsored by Mayo Clinic. Primary endpoints: Sensitivity of FET PET results in comparison to histopathology, Specificity of FET PET results in comparison to histopathology and 1 more. Started Apr 2026; status: recruiting.
02
Drugs
O-(2-[18F]fluoroethyl)-L-tyrosine
03
Conditions
Cushing's disease (CD)pituitary adenoma
Beyond the preview
Go deeper on NCT07460232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07460232.